Myriad Genetics Inc. reports developments in molecular diagnostic testing and precision medicine, with recurring updates on tests that assess disease risk, disease progression, and treatment selection across medical specialties. Company news commonly covers the Cancer Care Continuum, Prenatal Health, and Mental Health businesses, including test volume trends, average revenue per test, earnings results, and financial guidance.
Updates also address Myriad's oncology diagnostics and research programs, including MyChoice CDx, Precise MRD, Prolaris, hereditary cancer testing, GeneSight, and prenatal testing products. News themes include companion diagnostic approvals, clinical data presentations, commercial launches, collaborations, and investor healthcare conference participation.
New nationwide poll results reveal significant mental health challenges among seniors, with 61% of respondents age 65+ reluctant to seek treatment for depression. Surprisingly, 33% believe they can manage their symptoms independently. The GeneSight® Mental Health Monitor indicates that stigma surrounding mental health is prevalent, as many seniors view depression as a normal aspect of aging. Experts urge that depression is a treatable condition, comparable to physical ailments. The survey, conducted with a margin of error of ±5%, highlights the critical need for improved awareness and treatment.
Myriad Genetics (MYGN) has expanded its myChoice® tumor testing to Europe and China, enhancing access to its genomic instability test. This test identifies patients likely to benefit from DNA-damaging drugs. Recent trial data showed Lynparza, combined with bevacizumab, improved progression-free survival in HRD-positive ovarian cancer patients. Myriad will collaborate with leading pathology institutes in Germany and France for testing, while partnering with Burning Rock Biotech in China to broaden market reach. This initiative aligns with Myriad's goal of advancing precision medicine globally.
Myriad Genetics (NASDAQ: MYGN) presented findings at the American College of Rheumatology (ACR) meeting, highlighting the significance of Vectra testing and three biomarkers in predicting cardiovascular (CV) risks in rheumatoid arthritis (RA) patients. The studies indicated Vectra as a strong predictor of joint damage, outperforming subjective measures. Findings showed a hazard ratio of 3.99 for major CV events with Vectra, emphasizing its potential for guiding treatment decisions. Myriad seeks to leverage this data to enhance patient outcomes and inform clinicians.
Myriad Genetics reported financial results for Q3 2020, revealing revenues of $145.2 million, a 56% sequential increase but a 22% decline year-over-year. Test volumes improved to 90% of pre-pandemic levels. GAAP operating income rose by $28.7 million sequentially, while GAAP EPS improved to ($0.20). The company identified over $40 million in annualized cost savings and announced a strategic review of its Myriad RBM and Dermatology units. Myriad continues to adapt to COVID-19 impacts, aiming for sustainable growth and operational excellence.
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced its quarterly earnings conference call for the period ending September 30, 2020, scheduled for 5 p.m. EST on November 9, 2020. Key executives, including CEO Paul J. Diaz and CFO R. Bryan Riggsbee, will discuss the company's financial performance and business updates during the call. Investors can join via a dedicated conference line or through a live webcast available on Myriad's official website. This call will provide insights into the company's financial metrics and strategic direction.
Myriad Genetics (NASDAQ: MYGN) announced that its EndoPredict® breast cancer prognostic test has received a positive evaluation from Germany's Federal Joint Committee (G-BA). This approval allows EndoPredict to be available for all patients with statutory health insurance in Germany, aiding in personalized chemotherapy decisions for early-stage breast cancer patients. The test has been recommended globally by several medical guidelines and is already accessible in multiple European countries. Myriad aims to expand access to this critical test in the German healthcare system.
Myriad Genetics (NASDAQ: MYGN) has filed its fiscal year 2020 proxy statement, announcing significant changes to its board structure, executive compensation, and governance policies. By year-end, two-thirds of the board will consist of new members with expertise in healthcare and technology. New policies include shifting to majority voting for directors, implementing a retirement age for directors, and enhancing board diversity to 44%. Additionally, changes to executive compensation tie bonuses to financial performance and adjust the fiscal year end from June 30 to December 31 for better alignment with industry standards.
Myriad Genetics (NASDAQ: MYGN) expands its Board of Directors by electing Rashmi Kumar, effective immediately. Kumar, age 51, is the Senior Vice President and Global Chief Information Officer at Hewlett Packard Enterprise, with previous experience at McKesson Corporation as Chief Information Officer. Her expertise in IT transformation, AI, and data analytics is expected to enhance Myriad's capabilities in molecular diagnostics and precision medicine. The board now consists of 12 members, signifying an effort to bolster strategic insights and operational growth.
Myriad Genetics (NASDAQ: MYGN) announced that its myChoice® CDx test has been included in new ASCO guidelines for PARP inhibitors in advanced ovarian cancer treatment. The guidelines recommend myChoice CDx for women with specific BRCA mutations and genomic instability to guide therapy. ASCO's endorsement follows several studies aimed at improving outcomes for ovarian cancer patients. The American Cancer Society estimates 21,750 new ovarian cancer cases and 13,940 deaths in 2020, highlighting the test's potential impact on patient care.
Myriad Genetics, Inc. (NASDAQ: MYGN) has appointed Paul J. Diaz as President and CEO, effective August 13, 2020. Mr. Diaz, with over 30 years in healthcare leadership, aims to lead the company's growth and enhance patient care. His experience includes over a decade as CEO of Kindred Healthcare, where he expanded the business significantly. The Board expressed confidence in his vision and operational skills, emphasizing the importance of high-quality patient care and innovative services. This leadership change is expected to support Myriad's mission of transforming patients' lives through molecular diagnostics.